Skip to content
DataLookout
Menu

NCT06219239

Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

StatusTerminated
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 2 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Suboptimal treatment response
    • Eligibility criteria expanded, about 40 words
    • Study completion date changed from estimate of Dec 31, 2026 to Dec 31, 2025
    • Site details revised
  2. Study First Submitted
  • Stopped: terminated, suspended or withdrawn

Endpoints

Primary

The number, frequency and severity of adverse events (AE) after reinfusion of KL003 drug products
Timeframe: within 6 months
The proportion of participants who meet the definition of transfusion independence (TI) for at least 6 months
Timeframe: Up to 24 months post transplant

Arms and interventions

KL003 cell injection Drug ProductExperimental

Traditional myeloablative conditioning regimen consists of Busulfan, which may increase the risk of irreversible pulmonary fibrosis, VOD, and infertility due to potential serious toxicity. In this study, we intend to use genetic hematopoietic stem cells (lentivirus transduction) transfusion with no conditioning regimen, which could avoid toxicity due to chemotherapy drugs.

Genetic: KL003 cell injection Drug Product

Sites

1 site in 1 country

  • Institute of Hematology & Blood Diseases HospitalTianjin, Tianjin Municipality, China